Cellectar Biosciences, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
In May 2026, Cellectar closed a registered direct offering raising ~$31.7M in net proceeds (upfront from ~$35M offering plus up to $105M in milestone-based securities) from institutional investors and management. Cash position grew from $13.2M (Dec 2025) to $34.0M (June 2026). Proceeds fund the Phase 3 confirmatory trial of iopofosine I-131 in Waldenström macroglobulinemia (WM); site activation began, first patient expected early 2027, NDA planned mid-2027 under FDA Accelerated Approval. Phase 2b CLOVER WaM data showed 87.5% ORR and 79.2% MRR in post-BTKi patients (n=24); Phase 1b CLR 125 (triple-negative breast cancer) enrollment initiated.
Why this rating
Capital raise (~2.5× company market cap) extends runway to Q2 2027, enables pivotal Phase 3 trial. Multiple clinical milestones and regulatory path (Breakthrough Designation, Accelerated Approval) reduce execution risk. Transforms cash position materially relative to $12.8M market cap.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.